Tag: molecular imaging and neuroendocrine tumors
Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations (updated January 26, 2019)
April 6, 2017
The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.
PLEASE SCROLL DOWN FOR A STATE-BY STATE LIST … READ MORE
